Markets trade flat; pharma stocks gain

Reuters BENGALURU | Updated on July 02, 2021

With struggling to get momentum, indices are set for over 1 per cent weekly loss.

Indian shares were on track to record a more than 1 per cent weekly loss as they struggled for momentum, after hitting all-time highs recently, due to a lack of fresh domestic triggers.

The benchmark indices on Friday were largely unchanged as losses in heavyweight information technology stocks offset gains in pharmaceutical companies.

By 0503 GMT, the blue-chip NSE Nifty 50 index was down 0.04 per cent at 15,673.25 and the S&P BSE Sensex slipped 0.04 per cent to 52,297.11.

While declining Covid-19 cases, easing of curbs and a surge in vaccinations have helped the Nifty and Sensex hit record highs as recently as Monday, they've been unable to make any headway since. For the week so far, they are down about 1.2 per cent.

Frontline stocks have not done very well this week, with gains seen more in mid-cap and smaller companies, said Aishvarya Dadheech, fund manager at Ambit Asset Management in Mumbai.

Markets are in a wait-and-watch mode, and upcoming first-quarter earnings will set the tone of how things move from here, he said.

In Mumbai trading, the Nifty IT index fell 0.64 per cent and was set for a second straight session of losses. IT major Tata Consultancy Services will be kicking off June-quarter earnings season next week.

The Nifty Pharma index gained as much as 0.89 per cent tohit a record high. The sector has witnessed a slew of positive Covid-19-related developments, such as Zydus Cadila applying for emergency-use approval for its vaccine, and Cipla getting an approval to import partner Moderna's shot.

The Nifty Bank index added 0.23 per cent.

The Reserve Bank of India said in its Financial Stability Report on Thursday that the impact of the pandemic on the balance sheet of banks has not been as severe as projected earlier.

Published on July 02, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like